Schroeder Thilo 4
4 · Revolution Medicines, Inc. · Filed Dec 9, 2024
Insider Transaction Report
Form 4
Schroeder Thilo
Director
Transactions
- Purchase
Common Stock
2024-12-05$46.00/sh+543,478$24,999,988→ 2,096,612 total(indirect: By Nextech Crossover I SCSP) - Purchase
Common Stock
2024-12-05$46.00/sh+760,869$34,999,974→ 760,869 total(indirect: By Nextech VIII SCSP)
Holdings
- 3,590,313(indirect: By Nextech V Oncology S.C.S., SICAV-SIF)
Common Stock
- 1,153,293(indirect: By Nextech VI Oncology SCSp)
Common Stock
Footnotes (4)
- [F1]Nextech Invest AG is the investment advisor of Nextech Crossover I SCSP ("Nextech Crossover"). The Reporting Person is a managing member of Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech Crossover. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
- [F2]Nextech Invest AG is the investment advisor of Nextech VIII SCSP ("Nextech VIII"). The Reporting Person is a managing member of Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VIII. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
- [F3]Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF ("Nextech V"). The Reporting Person is a managing member of Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech V. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
- [F4]Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The Reporting Person is a managing member of Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.